Sarcopenia clinical trials at UCLA
1 research study open to eligible people
Identifying Modifiable PAtient Centered Therapeutics (IMPACT) Frailty
open to eligible people ages 18 years and up
Frailty, the decline in physical and cognitive reserves leading to vulnerability to stressors is increasingly being recognized as a public health concern. Although multiple measures exist that can identify frail patients, very little is known about how or when to intervene. Sarcopenia, or the degree of muscle wasting, is closely correlated to frailty and patient outcomes. This is a prospective cohort study of critically ill patients to identify modifiable risk factors of sarcopenia, as potential targets to reduce frailty.
Los Angeles 5368361, California 5332921
Our lead scientists for Sarcopenia research studies include Cecilia Canales, MD, MPH.
Last updated: